Table 2.

ORs for specific tumor subtypes, by major invasive histologic type, among current versus never users of hormone therapy

Ductal
Lobular/tubular
Mixed ductal-lobular
P (ductal vs lob/tub)P (ductal vs mixed)P (mixed vs lob/tub)
n/n*OR (95% CI)n/nOR (95% CI)n/nOR (95% CI)
Grade
1221/932.60 (2.00-3.39)108/363.22 (2.15-4.82)17/45.62 (1.76-17.97)0.380.210.37
2461/3911.41 (1.20-1.65)288/1093.29 (2.58-4.20)52/272.34 (1.42-3.85)<0.00010.050.22
3+258/3190.99 (0.82-1.19)39/262.02 (1.18-3.44)14/131.52 (0.67-3.45)0.010.310.57
P (G1 vs G2)<0.00010.930.17
P (G1 vs G3+)<0.00010.170.07
Size
TI603/3651.74 (1.50-2.03)265/783.74 (2.84-4.92)53/193.26 (1.87-5.66)<0.00010.030.66
T2293/3291.18 (0.98-1.41)134/682.36 (1.72-3.24)28/191.86 (0.99-3.47)<0.0010.170.50
T3+26/740.52 (0.32-0.84)28/212.46 (1.31-4.59)2/22.38 (0.29-19.30)<0.0010.170.42
P (T1 vs T2)<0.010.030.19
P (T1 vs T3+)<0.00010.230.78
Nodes
0632/4341.60 (1.39-1.85)296/983.54 (2.75-4.55)60/193.82 (2.20-6.63)<0.0001<0.010.80
1209/2091.28 (1.03-1.58)85/392.51 (1.67-3.77)17/151.24 (0.60-2.55)<0.010.930.09
2+54/1060.69 (0.48-0.99)32/222.06 (1.15-3.70)4/61.38 (0.35-5.43)<0.010.340.60
P (N0 vs N1)0.070.150.01
P (N0 vs N2+)<0.00010.090.18
ER/PR status
ER+ and/or PR+768/6111.49 (1.31-1.69)407/1642.97 (2.42-3.64)77/392.46 (1.62-3.73)<0.00010.020.42
ER− and PR−160/1881.02 (0.81-1.29)21/83.48 (1.47-8.28)2/50.62 (0.11-3.62)0.010.590.09
P<0.010.720.14
Her2/neu
Negative661/5441.42 (1.24-1.63)352/1293.24 (2.59-4.06)66/282.83 (1.77-4.55)<0.00010.010.61
Positive176/1881.10 (0.88-1.39)42/301.72 (1.04-2.86)9/121.07 (0.42-2.73)0.110.950.38
P0.050.020.07
  • Abbreviations: Lob, lobular; tub, tubular.

  • * n, the number of current hormone therapy users/never hormone therapy users. Sum of n differs from Table 1 because past hormone therapy users not included.

  • ORs adjusted for year of birth (continuous), study center, ever breastfed, ever benign breast tumor, number of mammograms, and family history of breast cancer.

  • All Ps represent tests for heterogeneity.